[HTML][HTML] Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without …
YK Song, G Lee, J Hwang, JW Kim… - Frontiers in …, 2023 - frontiersin.org
Objectives: Despite the ethnic differences in cardiovascular (CV) risks and recent increase in
the prescription of Janus kinase (JAK) inhibitors, limited evidence is available for their CV …
the prescription of Janus kinase (JAK) inhibitors, limited evidence is available for their CV …
Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational …
Objectives To compare the incidence of cardiovascular (CV) events in rheumatoid arthritis
(RA) treated with janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), or …
(RA) treated with janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), or …
[HTML][HTML] Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review
K Kraev, MG Geneva-Popova, BK Hristov, PA Uchikov… - Life, 2023 - mdpi.com
Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-
mediated diseases. While their efficacy is well-established, the safety concerns associated …
mediated diseases. While their efficacy is well-established, the safety concerns associated …
[HTML][HTML] Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A …
S Partalidou, D Patoulias, K Deuteraiou… - Mediterranean …, 2024 - ncbi.nlm.nih.gov
Objective: The aim of this study was to compare the risk of major cardiovascular events
(MACE) and venous thromboembolic events (VTE) between tumour necrosis factor (TNF) …
(MACE) and venous thromboembolic events (VTE) between tumour necrosis factor (TNF) …
[HTML][HTML] Riktlinjer för läkemedelsbehandling vid reumatoid artrit
I Gjertsson, J Lampa, A Svärd… - Svensk …, 2019 - riktlinjer.svenskreumatologi.se
Behandling av patienter med RA syftar till att dämpa sjukdomsaktivitet–om möjligt till av
klinisk remission–samt förebygga leddestruktion och en allvarlig sjukdomsutveckling på …
klinisk remission–samt förebygga leddestruktion och en allvarlig sjukdomsutveckling på …